MZB1 expression indicates poor prognosis in estrogen receptor‑positive breast cancer

Watanabe,Manabu; Shibata,Masahiro; Inaishi,Takahiro; Ichikawa,Takahiro; Soeda,Ikumi; Miyajima,Noriyuki; Takano,Yuko; Takeuchi,Dai; Tsunoda,Nobuyuki; Kanda,Mitsuro; Kikumori,Toyone; Kodera,Yasuhiro; Nagino,Masato

doi:10.3892/ol.2020.12059

MZB1 expression indicates poor prognosis in estrogen receptor‑positive breast cancer

Authors:
- Manabu Watanabe
- Masahiro Shibata
- Takahiro Inaishi
- Takahiro Ichikawa
- Ikumi Soeda
- Noriyuki Miyajima
- Yuko Takano
- Dai Takeuchi
- Nobuyuki Tsunoda
- Mitsuro Kanda
- Toyone Kikumori
- Yasuhiro Kodera
- Masato Nagino
View Affiliations

Affiliations: Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan, Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan, Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan
Published online on: September 4, 2020 https://doi.org/10.3892/ol.2020.12059
Article Number: 198
Copyright: © Watanabe et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) is the most common malignant tumor in females. Development of novel biomarkers or therapeutic targets may contribute toward the improvement of a patient's prognosis. Marginal zone B and B1 cell‑specific protein (MZB1) is an unfolded protein response‑related chaperone and mainly exists in the endoplasmic reticulum of B lymphocytes, although little is known regarding its role in BC cells. The present study aimed to investigate the significance of MZB1 expression in BC. To begin with, MZB1 mRNA expression levels in 13 BC cell lines and two non‑cancerous mammary cell lines were evaluated. Next, mRNA and protein expression of MZB1 in BC patient tumor specimens was evaluated to assess the association between expression and clinicopathological factors or prognosis. MZB1 mRNA expression levels were detectable in four estrogen receptor (ER)‑positive BC cell lines. When ratios of MZB1 mRNA expression levels between BC and non‑cancerous specimens were evaluated, patients with stage III disease exhibited a higher ratio than patients with stage 0/I/II disease (P=0.009). Using immunohistochemistry, patients with ER‑positive BC more frequently expressed MZB1, compared with patients with ER‑negative BC (P=0.003). In patients with ER‑positive BC, patients with MZB1‑positive BC experienced shorter disease‑free survival (DFS) times than patients with negative BC (P=0.026). Multivariate analysis of DFS demonstrated that MZB1 positivity was an independent prognostic factor (P=0.022). The results of the present study suggested that MZB1 expression may be associated with a more advanced stage of BC. Furthermore, in patients with ER‑positive BC, MZB1 may be a potential prognostic marker.

View Figures

View References

1	Global Burden of Disease Cancer Collaboration, ; Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and Disability-adjusted life-years for 32 cancer groups, 1990 to 2015 a systematic analysis for the global burden of disease study. JAMA Oncol. 3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
2	Iwata H: Future treatment strategies for metastatic breast cancer: Curable or incurable? Breast Cancer. 19:200–205. 2012. View Article : Google Scholar : PubMed/NCBI
3	Kanda M, Tanaka C, Kobayashi D, Tanaka H, Shimizu D, Shibata M, Takami H, Hayashi M, Iwata N, Niwa Y, et al: Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. Int J Cancer. 139:2290–2298. 2016. View Article : Google Scholar : PubMed/NCBI
4	Herold T, Mulaw MA, Jurinovic V, Seiler T, Metzeler KH, Dufour A, Schneider S, Kakadia PM, Spiekermann K, Mansmann U, et al: High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature. Leuk Lymphoma. 54:1652–1657. 2013. View Article : Google Scholar : PubMed/NCBI
5	Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arii S and Inazawa J: Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma. Clin Cancer Res. 18:3541–3551. 2012. View Article : Google Scholar : PubMed/NCBI
6	Rosenbaum M, Andreani V, Kapoor T, Herp S, Flach H, Duchniewicz M and Grosschedl R: MZB1 is a GRP94 cochaperone that enables proper immunoglobulin heavy chain biosynthesis upon ER stress. Genes Dev. 28:1165–1178. 2014. View Article : Google Scholar : PubMed/NCBI
7	Cox JS, Shamu CE and Walter P: Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell. 73:1197–1206. 1993. View Article : Google Scholar : PubMed/NCBI
8	Hochachka PW, Buck LT, Doll CJ and Land SC: Unifying theory of hypoxia tolerance: Molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA. 93:9493–9498. 1996. View Article : Google Scholar : PubMed/NCBI
9	Koumenis C: ER stress, hypoxia tolerance and tumor progression. Curr Mol Med. 6:55–69. 2006. View Article : Google Scholar : PubMed/NCBI
10	Fernandez PM, Tabbara SO, Jacobs LK, Manning FC, Tsangaris TN, Schwartz AM, Kennedy KA and Patierno SR: Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat. 59:15–26. 2000. View Article : Google Scholar : PubMed/NCBI
11	Fujimoto T, Onda M, Nagai H, Nagahata T, Ogawa K and Emi M: Upregulation and overexpression of human X-box binding protein 1 (hXBP-1) gene in primary breast cancers. Breast Cancer. 10:301–306. 2003. View Article : Google Scholar : PubMed/NCBI
12	Shibata M, Kanda M, Tanaka H, Umeda S, Miwa T, Shimizu D, Hayashi M, Inaishi T, Miyajima N, Adachi Y, et al: Overexpression of Derlin 3 is associated with malignant phenotype of breast cancer cells. Oncol Rep. 38:1760–1766. 2017. View Article : Google Scholar : PubMed/NCBI
13	Shibata M, Kanda M, Shimizu D, Tanaka H, Umeda S, Hayashi M, Inaishi T, Miyajima N, Adachi Y, Takano Y, et al: Expression of regulatory factor X1 can predict the prognosis of breast cancer. Oncol Lett. 13:4334–4340. 2017. View Article : Google Scholar : PubMed/NCBI
14	Cserni G, Chmielik E, Cserni B and Tot T: The new TNM-based staging of breast cancer. Virchows Archi. 472:697–703. 2018. View Article : Google Scholar
15	Shibata M, Kanda M, Shimizu D, Tanaka H, Umeda S, Miwa T, Hayashi M, Inaishi T, Miyajima N, Adachi Y, et al: RASEF expression correlates with hormone receptor status in breast cancer. Oncol Lett. 16:7223–7230. 2018.PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009. View Article : Google Scholar : PubMed/NCBI
18	Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and Tang P: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI
19	McGrath EP, Logue SE, Mnich K, Deegan S, Jäger R, Gorman AM and Samali A: The unfolded protein response in breast cancer. Cancers (Basel). 10:3442018. View Article : Google Scholar
20	Ansa-Addo EA, Thaxton J, Hong F, Wu BX, Zhang Y, Fugle CW, Metelli A, Riesenberg B, Williams K, Gewirth DT, et al: Clients and oncogenic roles of molecular chaperone gp96/grp94. Curr Top Med Chem. 16:2765–2778. 2016. View Article : Google Scholar : PubMed/NCBI
21	Belkaya S, Murray SE, Eitson JL, de la Morena MT, Forman JA and van Oers NS: Transgenic expression of microRNA-185 causes a developmental arrest of T cells by targeting multiple genes including Mzb1. J Biol Chem. 288:30752–30762. 2013. View Article : Google Scholar : PubMed/NCBI
22	Flach H, Rosenbaum M, Duchniewicz M, Kim S, Zhang SL, Cahalan MD, Mittler G and Grosschedl R: Mzb1 protein regulates calcium homeostasis, antibody secretion, and integrin activation in innate-like B cells. Immunity. 33:723–735. 2010. View Article : Google Scholar : PubMed/NCBI
23	Rajapaksa G, Thomas C and Gustafsson JÅ: Estrogen signaling and unfolded protein response in breast cancer. J Steroid Biochem Mol Biol. 163:45–50. 2016. View Article : Google Scholar : PubMed/NCBI
24	Andruska N, Zheng X, Yang X, Helferich WG and Shapiro DJ: Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer. Oncogene. 34:3760–3769. 2015. View Article : Google Scholar : PubMed/NCBI
25	Friedland JC, Smith DL, Sang J, Acquaviva J, He S, Zhang C and Proia DA: Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Invest New Drugs. 32:14–24. 2014. View Article : Google Scholar : PubMed/NCBI
26	Jhaveri K, Wang R, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S, Patil S, et al: A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Res. 19:892017. View Article : Google Scholar : PubMed/NCBI